- 関
- fosamprenavir、fosamprenavir calcium hydrate、fosamprenavir sodium
WordNet
- a white metallic element that burns with a brilliant light; the fifth most abundant element in the earths crust; an important component of most plants and animals (同)Ca, atomic number 20
PrepTutorEJDIC
- 『カルシウム』(金属元素;化学記号は『Ca』)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/11/20 22:08:11」(JST)
[Wiki en表示]
Fosamprenavir
|
|
Systematic (IUPAC) name |
{[(2R,3S)-1-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-3-({[(3S)-oxolan-3-yloxy]carbonyl}amino)-4-phenylbutan-2-yl]oxy}phosphonic acid
|
Clinical data |
Trade names |
Lexiva |
AHFS/Drugs.com |
monograph |
MedlinePlus |
a604012 |
Pregnancy
category |
|
Legal status |
|
Routes of
administration |
Oral |
Pharmacokinetic data |
Bioavailability |
Unknown |
Protein binding |
90% |
Metabolism |
Hydrolysed to amprenavir and phosphate in GI tract epithelium |
Biological half-life |
7.7 hours |
Excretion |
Fecal (as metabolites of amprenavir) |
Identifiers |
CAS Registry Number |
226700-81-8 N |
ATC code |
J05AE07 |
PubChem |
CID: 131536 |
DrugBank |
DB01319 Y |
UNII |
WOU1621EEG Y |
ChEMBL |
CHEMBL1664 Y |
NIAID ChemDB |
082186 |
Chemical data |
Formula |
C25H36N3O9PS |
Molecular mass |
585.608 g/mol
623.700 g/mol (calcium salt) |
SMILES
-
O=C(O[C@H]1CCOC1)N[C@@H](Cc2ccccc2)[C@H](OP(=O)(O)O)CN(CC(C)C)S(=O)(=O)c3ccc(N)cc3
|
InChI
-
InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 Y
-
Key:MLBVMOWEQCZNCC-OEMFJLHTSA-N Y
|
N (what is this?) (verify) |
Fosamprenavir (marketed by ViiV Healthcare as the calcium salt), under the trade names Lexiva (U.S.) and Telzir (Europe) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003, while the EMEA approved it on July 12, 2004. The human body metabolizes fosamprenavir in order to form amprenavir, which is the active ingredient. That metabolization increases the duration that amprenavir is available, making fosamprenavir a slow-release version of amprenavir and thus reducing the number of pills required versus standard amprenavir.
A head-to-head study with lopinavir[1] showed the two drugs to have comparable potency, but patients on fosamprenavir tended to have a higher serum cholesterol. Fosamprenavir's main advantage over lopinavir is that it is cheaper.
References
- ^ Eron J Jr, Yeni P, Gathe J Jr; et al. (2006). "The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial". Lancet 368 (9534): 476–82. doi:10.1016/S0140-6736(06)69155-1. PMID 16890834.
Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
|
|
Entry/fusion inhibitors
(Discovery and development) |
- gp41 (Enfuvirtide (ENF, T-20))
- CCR5 (Maraviroc (MVC)
- Vicriviroc†, Cenicriviroc†, PRO 140†)
- CD4 (Ibalizumab†)
- gp120 (Fostemsavir†)
|
|
Reverse-transcriptase
inhibitors (RTIs) |
Nucleoside and
nucleotide (NRTI) |
- Nucleoside analogues/NRTIs: Abacavir (ABC)°#
- Emtricitabine (FTC)°#
- Lamivudine (3TC)°#
- Didanosine (ddI)#
- Zidovudine (AZT, ZDV)#
- Apricitabine†
- Stampidine†
- Elvucitabine†
- Racivir†
- Amdoxovir†
- Stavudine (d4T)#
- Zalcitabine (ddC)◊
- Festinavir†
- Nucleotide analogues/NtRTIs: Tenofovir disoproxil fumarate (TDF)°#
- Tenofovir alafenamide fumarate (TAF)†
|
|
Non-nucleoside (NNRTI)
(Discovery and development) |
- (1st generation) Efavirenz (EFV)°#
- Nevirapine (NVP)#
- Delavirdine (DLV)◊
(2nd generation) diarylpyrimidines (Etravirine (ETR)
- Rilpivirine (RPV)°)
- Doravirine
|
|
|
Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI)) |
- Raltegravir (RAL)°
- Elvitegravir (EVG)°
- Dolutegravir (DTG)°
- Globoidnan A (experimental)
- MK-2048†
- BI 224436†
- Cabotegravir†
|
|
Maturation inhibitors |
|
|
Protease Inhibitors (PI)
(Discovery and development) |
1st generation |
- Fosamprenavir (FPV)
- Lopinavir (LPV)°#
- Nelfinavir (NFV)#
- Ritonavir (RTV)#
- Saquinavir (SQV)#
- Amprenavir (APV)◊
- Indinavir (IDV)◊#
- Telinavir
- Droxinavir
|
|
2nd generation |
- Atazanavir (ATV)°
- Darunavir (DRV)°
- Tipranavir (TPV)
|
|
|
Combined formulations |
- Abacavir/lamivudine°
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Darunavir/cobicistat
- Efavirenz/emtricitabine/tenofovir°
- Elvitegravir/cobicistat/emtricitabine/tenofovir°
- Emtricitabine/rilpivirine/tenofovir°
- Lamivudine/raltegravir
- Lamivudine/zidovudine
- Lopinavir/ritonavir°
- Tenofovir/emtricitabine°
|
|
Pharmacokinetic boosters |
- Ritonavir (r)
- Cobicistat (c)
|
|
Experimental agents |
Uncoating inhibitors |
|
|
Transcription inhibitors |
|
|
Translation inhibitors |
|
|
Other |
- Abzyme
- Calanolide A
- Ceragenin
- Cyanovirin-N
- Diarylpyrimidines
- Epigallocatechin gallate (EGCG)
- Foscarnet
- Fosdevirine†
- Griffithsin
- Hydroxycarbamide
- Miltefosine
- Portmanteau inhibitors
- Scytovirin
- Seliciclib†
- Synergistic enhancers
- Tre recombinase
- Zinc finger protein transcription factor
- KP-1461†
- BIT225†
|
|
Failed agents |
- Aplaviroc
- Atevirdine
- Brecanavir
- Capravirine
- Dexelvucitabine
- Emivirine
- Lersivirine
- Lodenosine
- Loviride
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent.
Index of viral disease
|
|
Description |
|
|
Disease |
- Systemic
- Cutaneous
- Zoster
- Human papillomavirus
- Zoonotic
- Symptoms and signs
|
|
Treatment |
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
- Nasta P1, Salmon D2, d'Arminio Monforte A3, Pimenta JM4, Cerini C1, Giralda M1, Winnock M5,6, Cozzi-Lepri A7.
- HIV clinical trials.HIV Clin Trials.2016 May;17(3):96-108. doi: 10.1080/15284336.2016.1150409. Epub 2016 Mar 16.
- OBJECTIVE: Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection.METHODS: A retrospective multicohort analysis was conducted. Subjects from three European cohorts who started FPV/r or lopinavi
- PMID 27125364
- [Mechanisms of action, pharmacology and interactions of dolutegravir].
- Ribera E1, Podzamczer D2.
- Enfermedades infecciosas y microbiología clínica.Enferm Infecc Microbiol Clin.2015 Mar;33 Suppl 1:2-8. doi: 10.1016/S0213-005X(15)30002-1.
- Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI), whose potential and binding half-life in the integrase are far superior to those of raltegravir and elvitegravir, conferring it with unique characteristics in terms of its genetic barrier to resistance and activity agai
- PMID 25858605
- Factors related to NT-proBNP levels in HIV patients aged over 40 years.
- Olalla J1, Crespo E1, De la Torre J1, Sempere M2, Del Arco A1, Prada JL1, Malvarez R1, Pérez J1, García-Alegría J1.
- AIDS research and therapy.AIDS Res Ther.2015 May 10;12:17. doi: 10.1186/s12981-015-0058-7. eCollection 2015.
- OBJECTIVE: To determine the levels of NT-pro BNP in HIV patients over 40 years who are receiving highly active antiretroviral therapy (HAART) and investigating potential independent clinical or laboratory factors.METHOD: We determine levels of NT-pro BNP in peripheral blood of HIV patients from Cos
- PMID 25960760
Related Links
- Fosamprenavir (marketed by ViiV Healthcare as fosamprenavir calcium), under the trade names Lexiva (U.S.) and Telzir (Europe) is a pro-drug of the protease inhibitor and antiretroviral drug amprenavir. The FDA approved it October 20, 2003 ...
★リンクテーブル★
[★]
- 英
- fosamprenavir、fosamprenavir calcium、fosamprenavir sodium、fosamprenavir calcium hydrate
- 関
- ホスアンプレナビル、ホスアンプレナビルカルシウム水和物、ホスアンプレナビルカルシウム、ホスアンプレナビルナトリウム
[★]
- 英
- fosamprenavir、fosamprenavir calcium、fosamprenavir calcium hydrate、fosamprenavir sodium
- 関
- ホサンプレナビル、ホスアンプレナビルカルシウム水和物、ホスアンプレナビルカルシウム、ホスアンプレナビルナトリウム
[★]
- 関
- fosamprenavir、fosamprenavir calcium、fosamprenavir calcium hydrate
[★]
- 英
- fosamprenavir calcium
- 関
- ホサンプレナビル、ホスアンプレナビル
[★]
- 関
- fosamprenavir、fosamprenavir calcium、fosamprenavir sodium
[★]
ホスアンプレナビル、ホサンプレナビル
- 関
- fosamprenavir calcium、fosamprenavir calcium hydrate、fosamprenavir sodium
- 同
- Lexiva, fos-APV
[★]